These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31715606)

  • 21. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
    Nascimento C; Ferreira F
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
    Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stromal Clusterin Expression Predicts Therapeutic Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer.
    Wang Y; Brodsky AS; Xiong J; Lopresti ML; Yang D; Resnick MB
    Clin Breast Cancer; 2018 Jun; 18(3):e373-e379. PubMed ID: 28890185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of tumor-infiltrating immune cells (mast cells, neutrophils and lymphocytes) on neoadjuvant chemotherapy response in breast carcinomas.
    Okcu O; Öztürk Ç; Yalçın N; Yalçın AC; Şen B; Aydın E; Öztürk AE
    Ann Diagn Pathol; 2024 Jun; 70():152301. PubMed ID: 38581761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy.
    Melichar B; Študentova H; Kalábová H; Vitásková D; Čermáková P; Hornychová H; Ryška A
    Anticancer Res; 2014 Mar; 34(3):1115-25. PubMed ID: 24596349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.
    Ladoire S; Mignot G; Dabakuyo S; Arnould L; Apetoh L; Rébé C; Coudert B; Martin F; Bizollon MH; Vanoli A; Coutant C; Fumoleau P; Bonnetain F; Ghiringhelli F
    J Pathol; 2011 Jul; 224(3):389-400. PubMed ID: 21437909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer.
    Sasada S; Kimura Y; Emi A; Masumoto N; Kadoya T; Arihiro K; Okada M
    Anticancer Res; 2020 Jun; 40(6):3395-3400. PubMed ID: 32487636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication.
    Burugu S; Asleh-Aburaya K; Nielsen TO
    Breast Cancer; 2017 Jan; 24(1):3-15. PubMed ID: 27138387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor.
    Chen WC; Lai YH; Chen HY; Guo HR; Su IJ; Chen HH
    Histopathology; 2013 Aug; 63(2):225-33. PubMed ID: 23738752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy.
    Oner G; Broeckx G; Van Berckelaer C; Zwaenepoel K; Altintas S; Canturk Z; Tjalma W; Berneman Z; Peeters M; Pauwels P; van Dam PA
    Cancer Med; 2023 Sep; 12(17):17901-17913. PubMed ID: 37553911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.
    Ravelli A; Roviello G; Cretella D; Cavazzoni A; Biondi A; Cappelletti MR; Zanotti L; Ferrero G; Ungari M; Zanconati F; Bottini A; Alfieri R; Petronini PG; Generali D
    Tumour Biol; 2017 Apr; 39(4):1010428317695023. PubMed ID: 28378631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer.
    Criscitiello C; Esposito A; Trapani D; Curigliano G
    Cancer Treat Rev; 2016 Nov; 50():205-207. PubMed ID: 27744144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.
    De Angelis C; Nagi C; Hoyt CC; Liu L; Roman K; Wang C; Zheng Y; Veeraraghavan J; Sethunath V; Nuciforo P; Wang T; Tsimelzon A; Mao S; Hilsenbeck SG; Trivedi MV; Cataldo ML; Pavlick A; Wolff AC; Weigelt B; Reis-Filho JS; Prat A; Gutierrez C; Osborne CK; Rimawi MF; Schiff R
    Clin Cancer Res; 2020 Feb; 26(3):738-745. PubMed ID: 31653641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
    Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
    Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.